Navigation Links
John A. MacPhee Resigns From Strativa Pharmaceuticals
Date:12/17/2010

WOODCLIFF LAKE, N.J., Dec. 17, 2010 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) announced today that John A. MacPhee, has resigned his positions as President of Strativa Pharmaceuticals and Executive Vice President of Par Pharmaceutical Companies to pursue other interests effective January 31, 2011.  Patrick G. LePore, Par Pharmaceutical Companies, Chairman, CEO and President, will assume day-to-day oversight of Strativa on an interim basis.

Patrick G. LePore states, "In six years, John has successfully built a valuable platform and product portfolio that establishes Strativa as one of the best positioned young specialty companies in the industry.  I thank him for his many contributions and wish him well in his future pursuits."  Mr. LePore continues, "We remain fully committed to the business model and to driving growth in both our generic and branded divisions."

About Strativa Pharmaceuticals

Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX), excels at finding, enhancing, and bringing to market drugs that make a meaningful difference to patients. For more information about Strativa, visit www.strativapharma.com.

About Par Pharmaceutical Companies

Par Pharmaceutical Companies, Inc. is a U.S.-based specialty pharmaceutical company.  Through its wholly owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals, it develops, manufactures and markets higher-barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals.  For press releases and other company information, visit www.parpharm.com.

Safe Harbor Statement

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein.  Risk factors that might affect such forward-looking statements include those set forth in Item 1A of the Company's most recent Annual Report on Form 10-K, in other of the Company's filings with the SEC from time to time, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and on general industry and economic conditions.  Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.


'/>"/>
SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Paul D. Duke Resigns From Mesas Board of Directors
2. Strativa Pharmaceuticals Signs Agreement With Swedish Orphan Biovitrum Regarding Nascobal®
3. FDA Approves Strativa Pharmaceuticals Zuplenz® (ondansetron) Oral Soluble Film
4. Strativa Pharmaceuticals Provides An Update On Zuplenz(R) (Ondansetron) Oral Soluble Film
5. Strativa Pharmaceuticals Development Partner, BioAlliance Pharma, Presents Phase III Study Results of Miconazole Lauriad(R) for the Treatment of Oropharyngeal Candidiasis
6. Strativa Pharmaceuticals Provides Product Pipeline Update
7. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
8. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
9. Poniard Pharmaceuticals Announces Plan for Voluntary Prepayment of Term Loan and Transfer to Nasdaq Capital Market
10. Savient Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
11. Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)... May 15, 2017 Enterin Inc., a privately-held CNS ... developing novel compounds to treat Parkinson,s disease (PD), has enrolled ... a Phase 1/2a randomized, controlled, multicenter study involving patients with ... enroll 50 patients over a 9-to-12-month period. The first stage ... patients with PD. Participating sites include Denver ...
(Date:5/11/2017)... , May 11, 2017  Thornhill Research Inc. ... been awarded an $8,049,024 USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery ... the Canadian Commercial Corporation (CCC) ( Ottawa, ... Systems to administer general anesthesia to patients requiring ... "The US Marine Corps have been a ...
(Date:5/10/2017)... May 10, 2017 Global Health Intelligence ... Latin America , published its 2017 ranking of the ... based on extensive data analysis from GHI,s hospitals database ... database for the region. The GHI database covers 86% of ... more than 130 data points for each institution in key ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... On May 24, the Congressional Budget Office ... U.S. House on May 4, would result in 23 million Americans losing their health ... the 2010 Patient Protection and Affordable Care Act (ACA). , “It is clear ...
(Date:5/26/2017)... ... May 26, 2017 , ... Rob Lowe acts as host and ... the series is on hiking in American. Viewers can reconnect with America as it ... of hiking. , Many consumers have looked for an inventive new place for a ...
(Date:5/26/2017)... ... May 26, 2017 , ... Centennial-based BluSky ... proceeds from its 14th Annual Clays for Kids fundraiser, to be held Friday, ... Colorado. , As part of BluSky’s partnership with The Adoption Exchange, BluSky ...
(Date:5/24/2017)... ... 2017 , ... Last month, representatives from Rendina Healthcare Real ... officials to celebrate the grand opening of the 87,000 square foot medical office/ICU ... its ongoing relationship with RWJBarnabas Health, New Jersey’s largest health system. Two years ...
(Date:5/24/2017)... ... May 24, 2017 , ... NucleusHealth ™, ... has received U.S. Food and Drug Administration (FDA) 510(k) clearance for ... secure cloud platform for medical image management. At the core is patented streaming ...
Breaking Medicine News(10 mins):